Bank of New York Mellon Corp Has $30.05 Million Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Bank of New York Mellon Corp lessened its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 2.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 384,844 shares of the company's stock after selling 10,405 shares during the quarter. Bank of New York Mellon Corp owned 0.78% of Prestige Consumer Healthcare worth $30,052,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Boston Trust Walden Corp lifted its holdings in shares of Prestige Consumer Healthcare by 43.5% during the fourth quarter. Boston Trust Walden Corp now owns 831,627 shares of the company's stock valued at $64,942,000 after acquiring an additional 252,089 shares during the period. Wellington Management Group LLP acquired a new stake in shares of Prestige Consumer Healthcare during the 3rd quarter worth about $6,342,000. Barclays PLC lifted its holdings in Prestige Consumer Healthcare by 346.3% during the 3rd quarter. Barclays PLC now owns 92,444 shares of the company's stock valued at $6,665,000 after purchasing an additional 71,730 shares during the last quarter. Edgestream Partners L.P. acquired a new position in Prestige Consumer Healthcare in the third quarter valued at about $3,947,000. Finally, Geode Capital Management LLC grew its stake in Prestige Consumer Healthcare by 4.0% during the third quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company's stock worth $95,678,000 after buying an additional 50,961 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on PBH shares. DA Davidson lifted their target price on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a research note on Friday, February 7th. StockNews.com downgraded Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research report on Monday. Oppenheimer increased their target price on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a report on Thursday, February 13th. Sidoti cut Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price target for the company. in a report on Monday, December 9th. Finally, Raymond James upgraded shares of Prestige Consumer Healthcare to a "moderate buy" rating in a research report on Thursday, December 19th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $92.60.

Remove Ads

Prestige Consumer Healthcare Trading Down 2.3 %

Shares of PBH stock traded down $1.95 on Wednesday, reaching $83.14. 322,094 shares of the stock were exchanged, compared to its average volume of 333,925. The stock has a 50 day moving average price of $81.13 and a 200 day moving average price of $78.09. The stock has a market cap of $4.12 billion, a PE ratio of 19.50, a P/E/G ratio of 2.69 and a beta of 0.46. Prestige Consumer Healthcare Inc. has a one year low of $62.35 and a one year high of $90.04. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. Equities research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.